[KSCI] Korea Science Citation Index Service

http://dx.doi.org/10.4333/KPS.2005.35.3.151

A Novel Drug Delivery System Design for Meloxicam

Kim, Hyun-Jo (Product Development & Planning, Kolon Pharm. Inc.)
Lee, Il-Kyu (R&D Center, Daejun Research Complex)

Publication Information

Journal of Pharmaceutical Investigation / v.35, no.3, 2005 , pp. 151-155 More about this Journal

Abstract

A drug delivery system(DDS) for practically insoluble meloxicam was developed and evaluated by dissolution study. A novel DDS is two layered system, where the first layer is consisted of gas-forming agent for an immediate release and the second layer is composed of metolose SR(HPMC) for sustained release. This bilayered tablets were manufactured by using manual single punch machine. The results of dissolution study showed an initial burst release followed by sustained release for the experimental period time. From a pharmaceutical point of view, the designed DDS for meloxicam would be informative system in terms of poorly soluble analgesic medicines.

Keywords

Drug delivery system; practically insoluble drug; meloxicam; effervescent tablet; HPMC; analgesics;

Citations & Related Records

Reference

1	B. Lund, M. Dialel, R. Bluhmki and A double-blind, randomized placebo-controlled study of efficacy and tolerance of meloxicam treatment in patients with osteoarthritis of the knee. Scand J. Rheumatol, 27, 32-37 (1998) DOI ScienceOn
2	D. Vocum, D. Hall, and P. Ruszko, Meloxicam osteoarthritis team. Efficacy and safety of meloxicam in the treatment of osteoarthritis. Arthr Rheum., 42(Suppl), S147 (1999)
3	Ludipress, Technical information, BASF Chem. Co., Supersedes issue of October 2001, September, 2003
4	Metolose SR (Hypromellose), Technical note, ShinEtsu Chem. Co., issued on October, 2002
5	B. Pose-Vilamovo, C. Rodriguez-Tenreiro, J.-F. Rosa dos Santos, J. Vazquez-Doval, A. Concheiro, C. Alvarez-Lorenzo and J.-J. Torres-Labandeira, Modulating drug release with cyclodextrins in hydroxypropyl methylcellulose gels and tablets. J. Control Release. 10;94(2-3), 351-363 (2004)
6	R.-O. Williams 3rd, M.-A .Sykora and V. Mahaguna, Method to recover a lipophilic drug from hydroxypropyl methylcellulose matrix tablets. AAPS Pharm. Sci. Tech. Jun, 9;2(2):E8 (2001)
7	D.-X. Zhejiang, B. Xue and Y.-X. Ban. Investigation on release model of insoluble drug in hydroxypropyl methycellulose matrix tablets, 33(3), 225-228 (2004)
8	R. Banerjee, H. Chakraborty and M. Sarkar, Host-Guest complexation of oxicam NSAIDs with ${\beta}$ -cyclodextrin, Biopolymers, 75(4), 355-365 (2004) DOI ScienceOn
9	M. Pairet, J. van Ryn, H. Schierok, A Mauz, G. Trummlitz and G. Engelhardt, Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4'-isomer. lnflamm Res., 47(6), 270-276 (1998) DOI ScienceOn
10	Rxlist, Mobic, Meloxicam, Pharmacology & Clinical review, US medicinal information
11	M.-M. Ghorab, H.-M. Abdel-Salam, M.-A EI-Sayad and M.-M. Mekhel, Tablet formulation containing meloxicam and beta-cyclodextrin: Mechanical characterization and bioavailability evaluation, AAPS Pharm. Sci. Tech., 27(5) , e59 (2004)
12	S. Gupta and L.-J. Crofford, An Update on specific COX-2 inhibitors: The COXIBs, Bulletin on the Rheumatic Disease., 50(1), 5245-5248 (2001)
13	E-M. Andreas, K.-D. Christine, H. Nina, H. Stefan, S. Jens and K.-H. Juergen, Water-so;uble meloxicam granulates, PCT W02004037264
14	K. Laura, P. John, C.-R. Eugene and R. Tuula, Nanoparticulate meloxicam formulations, US patent US2004229038
15	S. Baroota, S.-P. Agarwal, Meloxicam complexation with ${\beta}$ -cyclodextrin: influence on the anti-inflammatory and ulcerogenic activity, 58, 73-74 (2003)
16	N.-B. Naidu, K.P.R. Chowdary, K.Y.R. Murthy, Y. Satyanarayana, A.-R. Hayman and G. Heeket, Physicochemical characterization and dissolution properties of meloxicam-cyclodextrin binary systems, Journal of Pharmaceutical and Biomedical Analysis, 35, 75-86 (2004) DOI ScienceOn
17	J. Dequeker, and F. degner, Inflammation Research Editorial, lnflamm. Res., 50, Supplement 1 S3-S4 (2001)
18	E.-M. Lemmel, W. Bolten, R. Burgos-Vargns, P. Platt, M. Nissila, D. Sahlberg, et al., Efficacy and safety of meloxicam in patients with rheumatoid arthritis, J. Rheumatopl., 24, 282-290 (1997)
19	M. Dougados, A. Gueguen, J.-P. Nakache, I. Veys, E.-M. Zeildler, et a!., Ankylosing spondylitis: What is the optimum duration of a clinical study? A one year versus a 6 weeks nonsteroidal anti-inflammatory drug trial. Rheumatology, 38, 235-244 (1999) DOI ScienceOn
20	D. Duchene, D. Wouessidiewe, Pharmaceutical uses of cyclodextrins and derivatives, Drug Dev. lnd. Pharm., 16, 2487-2499 (1990) DOI
21	O. Berkers, E.Y. Uijioridal, J.-H. Haijnen, A. Bult and W.-J. Underberg, Cyclodextrins in the pharmaceutical field. Drug Dev. lnd. Pharm. 17, 1503-1549 (1991) DOI